Expression of the embryological morphogen Nodal in stage III/IV melanoma

Melanoma Research

Volumn 21, Issue 6, 2011, Pages 491-501

  Hooijkaas, Anna I ^a   Gadiot, Jules ^a   Van Boven, Hester ^a   Blank, Christian ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

immunotherapy; Nodal; patient survival; prognostic marker; stage III IV melanoma

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DENDRITIC CELL VACCINE; PROTEIN NODAL;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE COURSE; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKIN CARCINOGENESIS; SKIN METASTASIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; EMBRYONIC DEVELOPMENT; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; MORPHOGENESIS; NEOPLASM STAGING; NODAL PROTEIN; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; VALIDATION STUDIES AS TOPIC; YOUNG ADULT;

EID: 80955166963     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32834bf37b     Document Type: Article

References (51)

1. Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer - the role of sunlight. Adv Exp Med Biol 2008; 624:89-103.
2. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622-3634.
3. Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res 2000; 10:81-92.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
5. Hocker TL, Singh MK, Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 2008; 128:2575-2595.
6. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 368:711-723.
7. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 2007; 33:665-680.
8. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
9. Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. Cancer Res 2003; 63:5669-5673.
10. Haluska F, Pemberton T, Ibrahim N, Kalinsky K. The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol 2007; 34:546-554.
11. Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, et al. Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 2005; 65:9851-9860.
12. Smalley KS, Nathanson KL, Flaherty KT. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009; 69:3241-3244.
13. Postovit LM, Margaryan NV, Seftor EA, Kirschmann DA, Lipavsky A, Wheaton WW, et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci USA 2008; 105:4329-4334.
14. Topczewska JM, Postovit LM, Margaryan NV, Sam A, Hess AR, Wheaton WW, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med 2006; 12:925-932.
15. Krebs LT, Iwai N, Nonaka S,Welsh IC, Lan Y, Jiang R, et al. Notch signaling regulates left-right asymmetry determination by inducing Nodal expression. Genes Dev 2003; 17:1207-1212.
16. Schier AF. Nodal signaling in vertebrate development. Annu Rev Cell Dev Biol 2003; 19:589-621.
17. Smith WC, McKendry R, Ribisi S Jr, Harland RM. A nodal-related gene defines a physical and functional domain within the Spemann organizer. Cell 1995; 82:37-46.
18. Tian T, Meng AM. Nodal signals pattern vertebrate embryos. Cell Mol Life Sci 2006; 63:672-685.
19. James D, Levine AJ, Besser D, Hemmati-Brivanlou A. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development 2005; 132:1273-1282.
20. Shen MM. Nodal signaling: developmental roles and regulation. Development 2007; 134:1023-1034.
21. Vallier L, Reynolds D, Pedersen RA. Nodal inhibits differentiation of human embryonic stem cells along the neuroectodermal default pathway. Dev Biol 2004; 275:403-421.
22. Vallier L, Alexander M, Pedersen RA. Activin/Nodal and FGF pathways cooperate to maintain pluripotency of human embryonic stem cells. J Cell Sci 2005; 118:4495-4509.
23. Collignon J, Varlet I, Robertson EJ. Relationship between asymmetric nodal expression and the direction of embryonic turning. Nature 1996; 381:155-158.
24. Schier AF, Shen MM. Nodal signalling in vertebrate development. Nature 2000; 403:385-389.
25. Strizzi L, Postovit LM, Margaryan NV, Lipavsky A, Gadiot J, Blank C, et al. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol 2009; 4:67-78.
26. Yu L, Harms PW, Pouryazdanparast P, Kim DS, Ma L, Fullen DR. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions. Mod Pathol 2010; 23:1209-1214.
27. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003; 3:411-421.
28. McAllister JC, Zhan Q, Weishaupt C, Hsu MY, Murphy GF. The embryonic morphogen, Nodal, is associated with channel-like structures in human malignant melanoma xenografts. J Cutan Pathol 2010; 37 (Suppl 1):19-25.
29. Hendrix MJ, Seftor EA, Chu YW, Seftor RE, Nagle RB, McDaniel KM, et al. Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential. J Natl Cancer Inst 1992; 84:165-174.
30. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 2001; 98:8018-8023.
31. Adamson ED, Minchiotti G, Salomon DS. Cripto: a tumor growth factor and more. J Cell Physiol 2002; 190:267-278.
32. Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, et al. Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res 2006; 12:5158-5164.
33. Gong YP, Yarrow PM, Carmalt HL, Kwun SY, Kennedy CW, Lin BP, et al. Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival. Eur J Surg Oncol 2007; 33:438-443.
34. Bianco C, Strizzi L, Ebert A, Chang C, Rehman A, Normanno N, et al. Role of human cripto-1 in tumor angiogenesis. J Natl Cancer Inst 2005; 97:132-141.
35. Ebert AD,Wechselberger C, Nees M, Clair T, Schaller G, Martinez-Lacaci I, et al. Cripto-1-induced increase in vimentin expression is associated with enhanced migration of human Caski cervical carcinoma cells. Exp Cell Res 2000; 257:223-229.
36. Strizzi L, Abbott DE, Salomon DS, Hendrix MJ. Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle 2008; 7:1931-1935.
37. Wechselberger C, Ebert AD, Bianco C, Khan NI, Sun Y, Wallace-Jones B, et al. Cripto-1 enhances migration and branching morphogenesis of mouse mammary epithelial cells. Exp Cell Res 2001; 266:95-105.
38. La Porta CA. Mechanism of drug sensitivity and resistance in melanoma. Curr Cancer Drug Targets 2009; 9:391-397.
39. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, et al. CD8+ enriched 'young' tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 2010; 16:6122-6131.
40. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 2010; 116:4139-4146.
41. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2:512-519.
42. Postovit LM, Seftor EA, Seftor RE, Hendrix MJ. Targeting Nodal in malignant melanoma cells. Expert Opin Ther Targets 2007; 11:497-505.
43. Strizzi L, Hardy KM, Seftor EA, Costa FF, Kirschmann DA, Seftor RE, et al. Development and cancer: at the crossroads of Nodal and Notch signaling. Cancer Res 2009; 69:7131-7134.
44. Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2010; 117:2192-2201.
45. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 2005; 102:6092-6097.
46. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res 2006; 19: 290-302.
47. Jeffs AR, Glover AC, Slobbe LJ, Wang L, He S, Hazlett JA, et al. A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One 2009; 4:e8461.
48. Molife R, Lorigan P, MacNeil S. Gender and survival in malignant tumours. Cancer Treat Rev 2001; 27:201-209.
49. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
50. Postovit LM, Margaryan NV, Seftor EA, Hendrix MJ. Role of nodal signaling and the microenvironment underlying melanoma plasticity. Pigment Cell Melanoma Res 2008; 21:348-357.
51. Hadrup SR, Bakker AH, Shu CJ, Andersen RS, van Veluw J, Hombrink P, et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009; 6:520-526.